INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 241 filers reported holding INTRA CELLULAR THERAPIES INC in Q1 2022. The put-call ratio across all filers is 0.55 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,849,451 | -21.3% | 73,900 | -4.4% | 0.20% | -11.7% |
| Q2 2023 | $4,894,003 | +273.9% | 77,290 | +219.8% | 0.22% | +246.9% |
| Q1 2023 | $1,308,806 | -59.7% | 24,170 | -60.6% | 0.06% | -62.4% |
| Q4 2022 | $3,247,700 | -20.8% | 61,370 | -30.4% | 0.17% | -25.4% |
| Q3 2022 | $4,103,000 | -20.3% | 88,180 | -2.2% | 0.23% | -17.1% |
| Q2 2022 | $5,147,000 | +108.9% | 90,180 | +123.9% | 0.28% | +159.4% |
| Q1 2022 | $2,464,000 | – | 40,270 | – | 0.11% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 700,000 | $42,833,000 | 8.57% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 308,819 | $18,897,000 | 7.82% |
| Vahanian & Associates Financial Planning Inc. | 45,533 | $2,786,000 | 6.44% |
| DCF Advisers, LLC | 238,500 | $14,594,000 | 6.39% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 50,956 | $20,930,000 | 4.72% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,531,923 | $93,738,000 | 2.86% |
| Nicholas Investment Partners, LP | 562,373 | $34,412,000 | 2.45% |
| Bellevue Group AG | 3,429,619 | $209,859,000 | 2.44% |
| WASATCH ADVISORS LP | 7,477,868 | $457,571,000 | 2.25% |
| Quantum Private Wealth, LLC | 73,772 | $4,514,000 | 1.95% |